Skip to main content
. Author manuscript; available in PMC: 2016 Jul 25.
Published in final edited form as: J Am Coll Cardiol. 2016 Jan 5;67(1):29–38. doi: 10.1016/j.jacc.2015.10.046

Table 3.

Projected Lifetime Costs, QALYs, and Cost-Effectiveness Ratios

Lifetime Costs ($) LYs or QALYs ICER ($/QALY) Probability <$50,000 per QALY Probability <$150,000 per QALY

TAVR SAVR Δ TAVR SAVR Δ
Base Case 207,478 189,629 17,849 4.149 3.825 0.324 55,090 40.3% 90.0%
Subgroup Analyses
    IF Access (n = 627) 202,799 191,479 11,320 4.101 3.887 0.214 52,897 42.6% 75.2%
    Non-IF Access (n = 120) 229,487 181,784 47,703 4.321 3.561 0.760 62,767 27.6% 83.1%
    STS PROM ≥ 7 (n = 376) 190,957 183,749 7208 3.449 3.417 0.032 225,250 25.4% 44.5%
    STS PROM <7 (n = 371) 222,812 196,842 25,970 4.808 4.285 0.523 49,656 46.6% 92.8%
    Male (n = 394) 196,144 186,397 9,747 3.911 3.814 0.098 99,459 26.7% 49.7%
    Female (n = 353) 219,025 194,354 24,671 4.377 3.874 0.502 49,145 50.0% 94.0%
    Age ≥ 85 yrs (n = 377) 176,420 165,977 10,443 3.060 2.848 0.211 49,493 50.1% 80.2%
    Age <85 yrs (n = 370) 237,939 215,022 22,917 5.223 4.852 0.370 61,938 31.8% 81.6%
Sensitivity/Scenario Analyses
    Effectiveness = LYs 207,478 189,629 17,849 5.469 5.055 0.414 43,114 63.9% 92.1%
    Discount rate 0% 230,921 210,433 20,488 4.878 4.478 0.400 51,220 47.0% 90.3%
    Discount rate 5% 195,540 178,922 16,618 3.776 3.488 0.288 57,701 35.8% 90.0%
    Long-term hazard ratio = 0.86 215,243 189,629 25,615 4.390 3.825 0.566 45,256 63.7% 99.3%
    No difference in 1 month QOL 207,478 189,629 17,849 4.138 3.832 0.306 58,330 33.3% 88.6%
    No costs in added LYs 116,717 106,113 10,604 4.149 3.825 0.324 32,728 70.8% 91.3%

ICER = incremental cost-effectiveness ratio; IF = iliofemoral; LY = life-year; QALY = quality-adjusted life-year; QOL = quality of life; STS PROM = Society of Thoracic Surgeons predicted risk of mortality. Other abbreviations as in Table 1.